INTRODUCTION

Despite laboratory and observational studies suggesting beneficial health effects of β-carotene supplementation on cancer and other diseases, 2 chemoprevention trials conducted in populations of smokers found the opposite (1, 2). The Alpha-Tocopherol Beta-Carotene Cancer Prevention (ATBC) Study showed that male smokers supplemented with 20 mg β-carotene/d had a greater incidence of lung cancer (18%) and overall mortality (8%) than did men who did not receive β-carotene supplements (1). Similarly, the Beta-Carotene and Retinol Efficacy Trial reported that, among heavy smokers and asbestos-exposed workers, those supplemented with a combination of 30 mg β-carotene/d and 25,000 IU retinyl palmitate/d had a greater incidence of lung cancer (28%) and overall mortality (17%) than did women and men who received placebo (2). Subsequent research aimed at elucidating the biology underlying the adverse effects of β-carotene has suggested putative mechanisms for the increased lung cancer rates, including increased retinoic acid catabolism in the lungs via induction of cytochrome p450 (CYP) enzymes (3–5); however, the relevance to the increased overall mortality rate is poorly understood.

To our knowledge, there are no published metabolomic studies of the biological response to supplementation with β-carotene. We therefore quantitatively assessed the pre- and postenrollment metabolomic profile of response to supplementation with β-carotene in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study.4

ABSTRACT

Background: Two chemoprevention trials found that supplementation with β-carotene increased the risk of lung cancer and overall mortality. The biologic basis of these findings remains poorly understood.

Objective: The objective was to compare the on-study change in metabolomic profiles of men randomly assigned to receive or not receive β-carotene supplements in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study.

Design: The ATBC Study was a randomized, double-blind, placebo-controlled, primary cancer prevention trial; participants were Finnish male smokers assigned to 1 of 4 intervention groups: 1) α-tocopherol, 2) β-carotene, 3) both, or 4) placebo. Fifty participants with both baseline and follow-up fasting serum samples were randomly selected from each of these groups. Metabolomic profiling was conducted by mass spectrometry. The association between change in each metabolite over time and trial assignment (β-carotene or no β-carotene) was estimated by linear regression.

Results: We measured 489 metabolites, and 17 changed significantly (P < 0.05) in response to β-carotene supplementation. More of these 17 metabolites were of xenobiotic origin than would be expected by chance (9 of 60, or 15%; P = 0.00004). We also found a suggestive association with 1,5-anhydroglucitol—a marker of glycemic control (β = −0.379, P = 0.0071).

Conclusions: Male smokers supplemented with β-carotene developed metabolomic profiles consistent with the induction of cytochrome P450 enzymes, the primary metabolizers of xenobiotics in humans. These findings may shed light on the increased mortality associated with β-carotene supplementation in the ATBC Study and suggest the need to explore potential interactions between medication use and dietary supplements, particularly among smokers. This trial was registered at clinicaltrials.gov as NCT00342992. Am J Clin Nutr 2013;98:488–93.

1 From the Nutritional Epidemiology Branch (AMM, SCM, SJW, and DA) and the Biostatistics Branch (JNS), Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Department of Health and Human Services, Bethesda, MD; Metabolon, Inc, Durham, NC (AME and EDK); and the Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland (JV).

2 Supported by the Intramural Research Program of the National Cancer Institute, NIH, US Public Health Service (grant nos. N01-CN-45165, N01-RC-45035, N01-RC-37004, HHSN26120100006C, and HHSN26120080001E).

3 Address correspondence to D Albanes, 9609 Medical Center Drive, 6E342, Bethesda, MD 20892-9704. E-mail: dda@nih.gov.

4 Abbreviations used: ATBC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention; CYP, cytochrome P450; GC, gas chromatography; LIMS, laboratory information management system; MS, mass spectroscopy; QC, quality control; UPLC/MS/MS2, ultraHPLC tandem mass spectroscopy.

Received March 20, 2013. Accepted for publication May 13, 2013. First published online June 26, 2013; doi: 10.3945/ajcn.113.062778.
fasting serum metabolome of men randomly assigned to receive β-carotene in the ATBC Study and compared the changes that occurred with supplementation with those not supplemented with β-carotene.

**SUBJECTS AND METHODS**

**Study population**

The ATBC Study was a double-blind, placebo-controlled, primary cancer prevention trial designed to test the influence of supplementation with α-tocopherol or β-carotene on cancer incidence (9). Men who were between 50 and 69 y of age and who smoked ≥5 cigarettes/d were recruited between 1985 and 1988 in southwestern Finland. Trial participants (n = 29,133) were randomly assigned to 1 of 4 groups based on a 2 × 2 factorial design: 1) α-tocopherol (dl-α-tocopheryl acetate (50 mg/d), 2) β-carotene (20 mg/d), 3) both supplements, or 4) placebo. Supplementation continued for 5 to 8 y until the trial ended on 30 April 1993. Fasting blood samples were collected from all participants during their baseline visit. In addition, blood samples were collected annually from a random sample of participants. The blood samples were divided into aliquots and stored at −70°C. Written informed consent was obtained from all trial participants, and the ATBC Study was approved by institutional review boards at both the US National Cancer Institute and the Finnish National Public Health Institute. For the current analysis, 50 individuals were chosen from each of the 4 intervention groups for a total sample of 200 individuals. To be eligible for inclusion, participants were required to 1) have both a pre- and postrandomization fasting serum sample available with the follow-up sample collected ≥1 y after the baseline blood collection (mean: 3.3 y; range 1.0–6.9 y) and start of supplementation, and 2) have no diagnosis of cancer within 5 y after the follow-up blood collection.

**Metabolomic analysis**

Metabolomic profiling was conducted on baseline and follow-up serum samples at Metabolon Inc (Durham, NC) according to the protocol described below.

**Sample accessioning**

Each sample received was accessioned into a laboratory information management system (LIMS) and was assigned by the LIMS a unique identifier that was associated with the original source identifier only. This identifier was used to track all sample handling, tasks, results etc. The samples (and all derived aliquots) were tracked by LIMS. All portions of any sample were automatically assigned their own unique identifiers by LIMS when a new task was created; the relation of these samples was also tracked. All samples were maintained at −80°C until processed.

**Sample preparation**

Samples were prepared as described previously (10). Briefly, sample extraction was conducted by using aqueous methanol, delivered by an automated liquid handler to remove the protein fraction while allowing maximum recovery of small molecules. The resulting extract was divided into 4 fractions: 1 for analysis by ultraHPLC tandem mass spectroscopy (UPLC/MS/MS²) in the positive mode, 1 for UPLC/MS/MS² (negative mode), 1 for gas chromatography–mass spectrometry (GC-MS), and 1 for backup. Samples were placed briefly on a TurboVap (Zymark) to remove the organic solvent. Each sample was then frozen and dried under vacuum. Samples were then prepared for the appropriate instrument, either UPLC/MS/MS² or GC-MS.

**UPLC/MS/MS²**

The sample extracts destined for UPLC/MS/MS² positive- and negative-mode analyses were reconstituted and analyzed as described previously (10) under Methods/UHPLC Analyses, with the exception that the data were collected by using a ThermoFisher Scientific Orbitrap Elite high-resolution/accurate mass mass spectrometer. Briefly, 2 of the dried extracts were reconstituted in acidic or basic LC-compatible solvents, respectively. The acidic reconstituted extract was analyzed under positive ion optimized MS conditions, and the basic extract was analyzed by using negative-ion MS optimized conditions in 2 independent injections by using separate dedicated columns. The Orbitrap Elite used a heated electrospray ionization source and orbitrap mass analyzer operated at 30,000 mass resolution, scanned 80–1000 m/z, and alternated between MS and data-dependent MS² scans by using dynamic exclusion.

**Gas chromatography–mass spectroscopy**

The samples destined for GC-MS analysis were redried under vacuum desiccation for a minimum of 24 h before being derivatized under dried nitrogen with the use of bistrimethyl-silyl-trifluoroacetamide. The GC column was 5% phenyl, and the temperature ramp was from 40° to 300°C in a 16-min period. Samples were analyzed on a Thermo-Finnigan Trace DSQ fast-scanning single-quadrupole mass spectrometer by using electron impact ionization. The instrument was tuned and calibrated for mass resolution and mass accuracy on a daily basis. The information output from the raw data files was automatically extracted as discussed below.

**Quality assurance/quality control**

For quality assurance/quality control (QC) purposes, additional samples were included with each day’s analysis. These samples included extracts of a pool of well-characterized human plasma, extracts of a pool created from a small aliquot of the experimental samples, and process blanks. QC samples were spaced evenly among the injections, and all experimental samples were randomly distributed throughout the run. A selection of QC compounds was added to every sample for chromatographic alignment, including those under test. These compounds were carefully chosen so as not to interfere with the measurement of the endogenous compounds.

**Data extraction and compound identification**

Raw data were extracted, peak-identified, and QC processed as described previously (10, 11). Briefly, compounds were identified by comparison of experimental data to the laboratory’s authenticated standard library of purified standards or recurrent unknown entities. This library contains the retention time/index, m/z of the intact standard and its fragmentation spectral data (MS² or MS/MS), and chromatographic data on all molecules present in the library. Biochemical identifications were based on
3 criteria: retention index within a narrow retention time/index window of the proposed identification, accurate mass match to the library +/- 0.005 amu, and the MS/MS forward and reverse scores between the experimental data and authentic standards. Although there may be similarities between these molecules based on one of these factors, the use of all 3 data points can be used to distinguish and differentiate biochemicals. More than 3000 commercially available purified standard compounds have been acquired and registered into LIMS for distribution to both the LC and GC platforms for determination of their analytic characteristics. A total of 516 compounds were identified in our samples; any compound with <5 nonmissing observations in either the baseline or follow-up sample was excluded, which left 489 metabolites for analysis. Metabolites were then grouped into 10 mutually exclusive chemical classes (amino acids, carbohydrates, cofactors and vitamins, energy metabolites, lipids, nonstandard amino acids, nucleotide metabolites, peptides, and xenobiotics) based on the available literature. For the analysis, amino acids were separated into the standard amino acids (ie, those that are precursors of proteins directly encoded by the genetic code) and nonstandard amino acids (ie, those not incorporated into proteins or encoded by the genetic code). Each batch of samples submitted for analysis contained blinded QC samples from this study’s participants as well as from another cohort. The median and IQR of the intraclass correlation coefficient across the metabolites was 0.84 (0.52–0.96). These intraclass correlation coefficients were similar to those seen previously in samples analyzed by this laboratory (12).

Statistical analysis

To account for batch variability, metabolite concentrations were divided by their batch’s median value. A total of 36 samples were included in each batch, and the baseline and follow-up blood samples from an individual were included in the same batch with one another. Normalized metabolite concentrations were then log transformed, and missing values were imputed to the minimum of nonmissing values. In our primary analysis, we modeled the association between change in log-imputed metabolite concentrations and trial assignment (ie, trial group assignment) with stratification by number of cigarettes smoked per day, alcohol consumption, duration of supplementation with β-carotene as compared with no β-carotene supplementation. Results for the 17 metabolites that changed in response to β-carotene supplementation at the nominal statistical level of $P < 0.05$ are shown in Table 2; for 489 metabolites, tests were performed by using SAS version 9.1.3 (SAS Institute).

RESULTS

Prerandomization characteristics of the study population by the trial β-carotene assignment are shown in Table 1. As expected, because of the randomized nature of the trial, the distributions of factors were well balanced by supplementation arm, with the exception of fruit intake, which was slightly higher among men in the β-carotene arm (Table 1). A total of 489 metabolites were measured in our analytic set. However, after correction for multiple comparisons, no compound changed significantly in fasting serum during supplementation with β-carotene as compared with no β-carotene supplementation. Results for the 17 metabolites that changed in response to β-carotene supplementation at the nominal statistical level of $P < 0.05$ are shown in Table 2; findings for all 489 metabolites appear elsewhere (see Supplemental Table 1 under “Supplemental data” in the online issue). Our results were very similar when we used change in serum β-carotene concentration as the exposure, rather than β-carotene trial assignment, both based on a Bonferroni correction for 9 tests. All analyses were performed on 19 August 2018.
overall and among the β-carotene group (data not shown). No statistically significant interaction was found between any of the top 17 metabolites and any of the following factors: duration of supplementation with β-carotene, number of cigarettes smoked per day, alcohol consumption, or trial α-tocopherol supplementation.

Examination of the chemical classes of the top 17 metabolites showed that a greater number than would be expected by chance alone were xenobiotics (9 of 60, 15%; \( P = 0.00004 \); Table 3).

A modest intercorrelation was observed between these 17 metabolites (Figure 1), and a few were highly correlated: 3-(3-hydroxyphenyl) propionate and 3-hydroxyhippurate (\( r = 0.93 \)) and 1-methylurate and 5-acetylamino-6-amino-3-methyluracil (\( r = 0.79 \)). It is of interest that all 9 of the xenobiotic metabolites among the top 17 metabolites increased with β-carotene supplementation (Table 2). No other chemical class was over- or underrepresented in the most statistically significantly associated metabolites (Table 3).

### DISCUSSION

In this analysis of the metabolomic profile of fasting serum in a controlled trial population of male smokers, we identified 17 metabolites that appeared to change in men supplemented with β-carotene. To our knowledge, this was the first study to use global metabolomics analysis to characterize the biological effect of supplementation with β-carotene. Several of the metabolites possibly altered in response to β-carotene supplementation provided potential biologic insights into the trial findings for β-carotene in the ATBC Study and Beta-Carotene and Retinol Efficacy Trial. One notable finding was the overrepresentation of xenobiotic metabolite signals among our most statistically significant associations with response to β-carotene, all of which showed increased concentrations during supplementation. CYP enzymes are primarily responsible for human xenobiotic metabolism, and previous experimental studies showed induction of several CYP isofoms.

<table>
<thead>
<tr>
<th>Metabolite</th>
<th>Chemical class</th>
<th>Number &gt; LOD</th>
<th>Effect size(^2)</th>
<th>( P ) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Threonine</td>
<td>Amino acid</td>
<td>200</td>
<td>-0.381</td>
<td>0.0067</td>
</tr>
<tr>
<td>1,5-Anhydroglucitol</td>
<td>Carbohydrate</td>
<td>200</td>
<td>-0.379</td>
<td>0.0071</td>
</tr>
<tr>
<td>Hippurate</td>
<td>Xenobiotics</td>
<td>200</td>
<td>0.363</td>
<td>0.0099</td>
</tr>
<tr>
<td>3-(3-Hydroxyphenyl) propionate</td>
<td>Nonstandard amino acid</td>
<td>158</td>
<td>0.357</td>
<td>0.0111</td>
</tr>
<tr>
<td>3-Hydroxyhippurate</td>
<td>Xenobiotics</td>
<td>198</td>
<td>0.351</td>
<td>0.0126</td>
</tr>
<tr>
<td>Dihydroferulic acid</td>
<td>Xenobiotics</td>
<td>77</td>
<td>0.350</td>
<td>0.0131</td>
</tr>
<tr>
<td>2-Hydroxyacetaminophen sulfate</td>
<td>Xenobiotics</td>
<td>24</td>
<td>0.334</td>
<td>0.0179</td>
</tr>
<tr>
<td>3,7-Dimethylurate</td>
<td>Xenobiotics</td>
<td>158</td>
<td>0.318</td>
<td>0.0240</td>
</tr>
<tr>
<td>5-Acetylamino-6-amino-3-methyluracil</td>
<td>Xenobiotics</td>
<td>196</td>
<td>0.318</td>
<td>0.0241</td>
</tr>
<tr>
<td>β-Sitosterol</td>
<td>Lipid</td>
<td>114</td>
<td>-0.314</td>
<td>0.0262</td>
</tr>
<tr>
<td>Xylose</td>
<td>Carbohydrate</td>
<td>174</td>
<td>-0.296</td>
<td>0.0358</td>
</tr>
<tr>
<td>1-Methylurate</td>
<td>Xenobiotics</td>
<td>200</td>
<td>0.294</td>
<td>0.0372</td>
</tr>
<tr>
<td>2-Hydroxyisobutyrate</td>
<td>Nonstandard amino acid</td>
<td>200</td>
<td>0.293</td>
<td>0.0378</td>
</tr>
<tr>
<td>10-Nonadecenoate (19:1n−9)</td>
<td>Lipid</td>
<td>200</td>
<td>0.285</td>
<td>0.0434</td>
</tr>
<tr>
<td>Catechol sulfate</td>
<td>Xenobiotics</td>
<td>200</td>
<td>0.283</td>
<td>0.0451</td>
</tr>
<tr>
<td>Cinnamoylglycine</td>
<td>Xenobiotics</td>
<td>185</td>
<td>0.280</td>
<td>0.0475</td>
</tr>
<tr>
<td>7-Ketodeoxycholate</td>
<td>Lipid</td>
<td>63</td>
<td>0.277</td>
<td>0.0498</td>
</tr>
</tbody>
</table>

\( ^1 \) ATBC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention; LOD, limit of detection.

\( ^2 \) Effect size denotes the change in metabolite level (expressed in number of SDs on the log scale) for the β-carotene arm compared with the no β-carotene arm. The effect sizes and \( P \) values were estimated by linear regression.

<table>
<thead>
<tr>
<th>Chemical class</th>
<th>No. of identified metabolites</th>
<th>No. of metabolites associated with β-carotene supplementation at ( P &lt; 0.05 )</th>
<th>( P ) value(^2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>489</td>
<td>17</td>
<td>0.000004</td>
</tr>
<tr>
<td>Xenobiotics</td>
<td>60</td>
<td>9 (15.0)</td>
<td>0.12</td>
</tr>
<tr>
<td>Lipids</td>
<td>181</td>
<td>3 (1.7)</td>
<td></td>
</tr>
<tr>
<td>Peptides</td>
<td>70</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>Carbohydrates</td>
<td>22</td>
<td>2 (9.1)</td>
<td></td>
</tr>
<tr>
<td>Amino acids(^3)</td>
<td>20</td>
<td>1 (5.0)</td>
<td></td>
</tr>
<tr>
<td>Nonstandard amino acids(^4)</td>
<td>88</td>
<td>2 (2.3)</td>
<td></td>
</tr>
<tr>
<td>Cofactors and vitamins</td>
<td>21</td>
<td>0 (0)</td>
<td>0.75</td>
</tr>
<tr>
<td>Energy metabolites</td>
<td>7</td>
<td>0 (0)</td>
<td>1.0</td>
</tr>
<tr>
<td>Nucleotide metabolites</td>
<td>20</td>
<td>0 (0)</td>
<td>1.0</td>
</tr>
</tbody>
</table>

\( ^1 \) Values in parentheses are percentages. ATBC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention.

\( ^2 \) Calculated by using Fisher’s exact test.

\( ^3 \) Amino acids are defined here as the 20 amino acids that are precursors to proteins and that are directly encoded by the universal genetic code. Nonstandard amino acids are those that are either not incorporated into proteins or not directly encoded by the universal genetic code.
in various tissues in response to supplementation with β-carotene, including CYP1A2 and CYP2E1 (3, 13). In fact, several of the top xenobiotic compounds identified in our analysis result from CYP1A2- or CYP2E1-mediated metabolism, including 3,7-dimethylurate and 1-methylurate. These are metabolites of theophylline, a drug used to treat asthma and chronic obstructive pulmonary disease and a metabolite of caffeine, and 5-acetyl-6-amino-3-methyluracil—a caffeine metabolite. Both theophylline and caffeine are substrates for CYP1A2. Another top signal was 2-hydroxyacetaminophen sulfate, an oxidation product of acetaminophen after metabolism by CYP2E1 (with CYP1A2 serving as a secondary pathway) (14). One possible explanation for these findings is that men who received the β-carotene supplement began taking more theophylline or acetaminophen or increased their caffeine intake during follow-up relative to the men who did not receive β-carotene. However, both caffeine and theophylline were measured as part of the metabolomic profile, and neither changed with β-carotene supplementation (caffeine: \( P = 0.75 \); theophylline: \( P = 0.33 \); see Supplementary Table 1 under “Supplemental data” in the online issue). Several important medications used to treat cardiovascular diseases are also metabolized by CYP1A2, including propranolol, tizanidine, verapamil, and warfarin. Thus, our findings support the hypothesis that interactions between β-carotene supplementation and prescription (and nonprescription) medications may have led to adverse mortality outcomes in the ATBC Study. To our knowledge, this was the first study to provide evidence supporting CYP enzyme induction as a result of β-carotene supplementation in humans. Another dietary supplement known to interact with prescription medications is St John wort—an herbal preparation commonly used for depression and a potent inducer of CYP2C9 and CYP3A4 known to cause multiple clinically significant drug interactions (15). Our analysis was limited to those metabolites that were both present in the samples from our study population and detectable by the metabolomic platform. Importantly, of the cardiovascular medications known to be metabolized by CYP1A2, only propranolol and verapamil were detectable by the metabolomic platform, and only verapamil was present in our study sample (and only in 2 participants at baseline and in 5 participants at the second blood collection). Thus, a lack of direct evidence of increased cardiovascular medication metabolites in the β-carotene group should not be considered evidence against the drug interaction hypothesis. Future studies should directly examine the interaction between β-carotene supplementation and cardiovascular medications.

We also found a suggestive association with 1,5-anhydroglucitol, a marker of glycemic control. This metabolite decreased with β-carotene supplementation, which suggests that those who received the β-carotene supplement experienced poorer glycemic control over time than did those who did not receive β-carotene. This finding is biologically plausible: animals exposed to tobacco smoke and supplemented with β-carotene have lower concentrations of retinoic acid and lower retinoic acid receptor-β expression (5), and a role for retinoids and retinoic acid receptor-β in the etiology and possibly even the treatment of type 2 diabetes has been described (16). Poorer glycemic control in the β-carotene arm could have implications for the finding of overall increased mortality among those receiving the β-carotene supplement in the ATBC Study because individuals with type 2 diabetes experience earlier mortality, particularly from cardiovascular disease (17), which was the most common cause of death among the ATBC Study participants (1). It should be noted, however, that other markers of glycemic control, such as glucose itself, were not altered by β-carotene supplementation (glucose: \( P = 0.57 \); see Supplementary Table 1 under “Supplemental data” in the online issue). However, 1,5-anhydroglucitol has been suggested as a better marker of glycemic fluctuations than fasting glucose concentrations, and these fluctuations are more strongly associated with cardiovascular disease mortality (18). Alternatively, this finding may be due to chance.

Our study had many important strengths, perhaps foremost of which was the randomized, double-blind, placebo-controlled design of the parent trial and our measurement of metabolomic profiles both before and after supplementation. In addition, the metabolomic platform we used permitted identification of a large number of metabolites (>500) and a more comprehensive characterization of the biological response to β-carotene supplementation. We did not discover individual metabolites that were statistically significantly altered by β-carotene supplementation after correction for multiple comparisons; therefore, such findings (eg, for 1,5-anhydroglucitol) may have been due to chance. At the same time, it should be noted that the representation of multiple xenobiotic metabolites among our top hits was statistically significantly greater than expected by chance alone, even after adjustment for 9 comparisons at a family-wise error rate of 0.05. Our study population was limited to male smokers of white ancestry, and the trial tested only one β-carotene dosage, which was both quite high and very bioavailable compared with food sources of β-carotene; these factors may have limited the generalizability of our findings. It is important to note that cigarette smoke is also a known inducer of CYP1A2 and CYP2E1, and alcohol intake is a known inducer of CYP2E1; experimental data show ferret lung CYP1A2 induction in response to both β-carotene and cigarette smoke, with the strongest change resulting from exposure to both (3), and the original trial finding in ATBC of an increased risk of lung cancer for those supplemented with β-carotene was stronger among men.
who drank more (19). We examined the association between our top metabolites and β-carotene supplementation stratified by these factors. However, we found no statistically significant interactions with either cigarettes smoked per day or alcohol intake, particularly the associations between the metabolites known to result from CYP1A2- or CYP2E1-mediated metabolism discussed above, and β-carotene supplementation did not differ by either smoking (<20 compared with ≥20 cigarettes/d: 3.7-dimethylurate $\beta_{<20} = 0.29$, $\beta_{\geq 20} = 0.26$, $P = 0.88$; 1-methylurate $\beta_{<20} = 0.31$, $\beta_{\geq 20} = 0.23$, $P = 0.73$; 2-hydroxyacinophen sulfate $\beta_{<20} = 0.41$, $\beta_{\geq 20} = 0.40$, $P = 0.98$) or alcohol intake (<median compared with ≥median intake: 3.7-dimethylurate $\beta_{\text{low}} = 0.43$, $\beta_{\text{high}} = 0.22$, $P = 0.46$; 1-methylurate $\beta_{\text{low}} = 0.25$, $\beta_{\text{high}} = 0.36$, $P = 0.70$; 2-hydroxyacinophen sulfate $\beta_{\text{low}} = 0.41$, $\beta_{\text{high}} = 0.24$, $P = 0.57$). Despite the lack of interaction in our study, however, there remains the possibility that the associations we observed may differ for nonsmokers, by alcohol consumption, or within those supplemented with a different dose of β-carotene.

In this metabolomics analysis of participants from a large, randomized trial of male smokers, we found that the metabolomic profiles of response to β-carotene supplementation point to induction of CYP1A2 and CYP2E1 and, possibly, to dysregulated glycemic control. These findings may shed light on the increased mortality resulting from β-carotene supplementation in the ATBC Study and call attention to the need for greater understanding of possible interactions between dietary supplements and other pharmacological agents.

The authors’ responsibilities were as follows—JV and DA: designed the research; AME and EDK: conducted the research; EDK: provided the essential materials; AMM and JNS: analyzed the data or performed the statistical analysis; AMM, JNS, SCM, SJW, JV, and DA: wrote the manuscript; and AMM: had responsibility for the final content. AME and EDK are employed by Metabolon Inc. AMM, JNS, SCM, SJW, JV, and DA had no conflicts of interest to disclose.

REFERENCES